Trump signals ‘aggressive’ tariffs on pharma imports, raising concerns for domestic companies

President Trump has threatened aggressive tariffs, potentially reaching 200%, on pharmaceutical imports, creating concerns for India’s export-driven pharma sector. Indian pharma stocks showed resilience, but companies like Aurobindo, Sun Pharma, and Lupin, which rely heavily on the US market, could face challenges. This move could disrupt the symbiotic relationship between the US and India’s healthcare ecosystems.